Nephros (NEPH) Competitors

Vivani Medical (NASDAQ:VANI) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.

Do insiders & institutionals have more ownership in VANI or NEPH?

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 44.3% of Vivani Medical shares are owned by company insiders. Comparatively, 4.1% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has stronger valuation and earnings, VANI or NEPH?

Nephros has higher revenue and earnings than Vivani Medical. Nephros is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$25.65M	-$0.45	-2.54
Nephros	$14.16M	1.22	-$1.58M	-$0.09	-18.17

Does the MarketBeat Community believe in VANI or NEPH?

Nephros received 9 more outperform votes than Vivani Medical when rated by MarketBeat users. However, 100.00% of users gave Vivani Medical an outperform vote while only 43.33% of users gave Nephros an outperform vote.

Company	Underperform	Outperform
Vivani Medical	Outperform Votes 4 100.00%	Underperform Votes No Votes
Nephros	Outperform Votes 13 43.33%	Underperform Votes 17 56.67%

Do analysts rate VANI or NEPH?

Vivani Medical currently has a consensus price target of $4.00, suggesting a potential upside of 249.34%. Nephros has a consensus price target of $5.00, suggesting a potential upside of 205.81%. Given Vivani Medical's higher possible upside, equities analysts clearly believe Vivani Medical is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nephros	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is VANI or NEPH more profitable?

Vivani Medical has a net margin of 0.00% compared to Nephros' net margin of -6.86%. Nephros' return on equity of -11.39% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-102.42%	-49.21%
Nephros	-6.86%	-11.39%	-8.30%

Which has more risk and volatility, VANI or NEPH?

Vivani Medical has a beta of 3.2, meaning that its stock price is 220% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Does the media refer more to VANI or NEPH?

In the previous week, Vivani Medical had 5 more articles in the media than Nephros. MarketBeat recorded 9 mentions for Vivani Medical and 4 mentions for Nephros. Nephros' average media sentiment score of 0.93 beat Vivani Medical's score of 0.45 indicating that Nephros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivani Medical	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nephros beats Vivani Medical on 8 of the 15 factors compared between the two stocks.